Results 61 to 70 of about 13,776 (222)

Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives Janus kinase inhibitors (JAKis) have been approved by the Therapeutic Goods Administration for severe alopecia areata (AA) in Australia. However, access is limited as JAKis are not currently subsidised on the Pharmaceutical Benefits Scheme for this indication. This study aimed to establish expert consensus on criteria for
Meryl Thomas   +23 more
wiley   +1 more source

Therapeutic Considerations Related to Finasteride Administration in Male Androgenic Alopecia and Benign Prostatic Hyperplasia [PDF]

open access: yes, 2017
Finasteride has been used extensively until now as a relative efficient therapeutic option for male androgenic alopecia and benign prostatic hyperplasia.
Baconi, Daniela L   +10 more
core   +1 more source

Breast and Nipple Dermatoses During Lactation

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Lactation and breastfeeding can present both psychological and physical challenges for breastfeeding mothers. In addition, many nursing mothers will also suffer from breast and nipple dermatoses during this period, compounding these difficulties. Common causes of breast and nipple dermatitis during lactation include eczema, psoriasis, mastitis,
Hamish Moore, Annabel Stevenson
wiley   +1 more source

Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Over 5000 patients are newly diagnosed with Alopecia areata (AA) in Australia each year. AA severity varies from a single small patch to complete loss of scalp hair, body hair including eyelashes and eyebrows. Approximately 40% of affected individuals experience only a single patch and achieve spontaneous, complete and durable remission within
Daniella Kushnir‐Grinbaum   +19 more
wiley   +1 more source

Thermogravimetric investigations of cream with minoxidil

open access: yesAktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, 2016
Minoxidil is one of the most effective and modern medications, which is used in modern trichology for hair growth stimulation in case of androgenic and other forms of alopecia.
I. V. Gnitko   +3 more
doaj   +1 more source

Trasplante de Pelo en la Alopecia Fibrosante Frontal: ¿Parte de la Solución? [PDF]

open access: yes, 2016
info:eu-repo/semantics ...
Camps-Fresneda, A, Mendes-Bastos, P
core   +1 more source

MSC‐Derived Secretome and Exosomes in Dermatology: Mechanisms, Therapeutic Opportunities, and Scientific Challenges—A Narrative Review

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Mesenchymal stromal cells (MSCs) exert their effects primarily through paracrine signaling via soluble factors and extracellular vesicles (EVs), especially exosomes. These acellular components offer regenerative and immunomodulatory benefits with fewer safety and logistical constraints than cell‐based therapies.
Marcela da Costa Pereira Cestari   +2 more
wiley   +1 more source

EFECTIVITY MINOXIDIL AS A TREATMENT OF ALOPECIA AREATA

open access: yese-Jurnal Medika Udayana, 2014
Alopecia areata is hair loss with patchy formation, the most common cause of alopecia nonscarring. Occurred in 1,7 % of Americans aged 50 years. Canoccurs in both sexes, all races and any age.
Wayan Evie Frida Yustin
doaj  

Evaluation of the Safety and Effectiveness of Oral Minoxidil in Children: A Systematic Review

open access: yesDermatology and Therapy
The minimal adverse-effect profile and positive clinical response of low-dose oral minoxidil (LDOM) have recently caused the drug to gain popularity for the treatment of hair disorders in adults.
Kimberly N. Williams   +2 more
doaj   +1 more source

Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study. [PDF]

open access: yes, 2019
BackgroundOnce-daily topical oxymetazoline cream 1·0% significantly reduced persistent facial erythema of rosacea in trials requiring live, static patient assessments.ObjectivesTo evaluate critically the methodology of clinical trials that require live ...
Alvandi, N   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy